| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 936707 | Neurobiology of Learning and Memory | 2011 | 9 Pages |
Previous research has indicated that the blockade of H3-type histamine receptors may improve attention and memory in normal rodents. The purpose of this study was to determine if ciproxifan, an H3 receptor antagonist, could alleviate the hyperactivity and cognitive deficits observed in a transgenic mouse model (APPTg2576) of Alzheimer’s disease. APPTg2576 mice displayed significantly greater locomotor activity than wild-type mice, but APPTg2576 mice provided with daily ciproxifan treatment showed activity levels that did not differ from wild-type mice. In the swim maze, APPTg2576 mice exhibited significantly longer escape latencies, but the APPTg2576 mice treated daily with ciproxifan had latencies that were indistinguishable from controls. In probe trials conducted one hour after the last training trial, ciproxifan-treated APPTg2576 mice spent more time near the previous platform location and made more crossings of this area than did saline-treated APPTg2576 mice. APPTg2576 mice also demonstrated a significant impairment in the object recognition task that was reversed by acute treatment with ciproxifan (3.0 mg/kg). These data support the idea that modulation of H3 receptors represents a novel and viable therapeutic strategy in the treatment of Alzheimer’s disease.
Research highlights► The H3 receptor antagonist, ciproxifan, improves spatial learning and memory in the APP mouse model of Alzheimer’s disease. ► Ciproxifan also alleviates deficits in object recognition memory seen in APP mice. ► APP mice exhibit locomotor hyperactivity and ciproxifan reduces this effect.
